Brian Calingaert
Overview
Explore the profile of Brian Calingaert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1385
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Foreman P, Margulis A, Alexander K, Shediac R, Calingaert B, Harding A, et al.
Orphanet J Rare Dis
. 2021 Jun;
16(1):253.
PMID: 34082800
Background: Phenylalanine hydroxylase (PAH) deficiency is an autosomal recessive disorder that results in elevated concentrations of phenylalanine (Phe) in the blood. If left untreated, the accumulation of Phe can result...
12.
Zografos L, Andrews E, Wolin D, Calingaert B, Davenport E, Hollis K, et al.
Pharmaceut Med
. 2020 Jan;
33(3):235-246.
PMID: 31933288
Background: As part of the risk-management plan (RMP) for aflibercept, materials have been developed to educate physicians in Canada on the key safety information and safe use for aflibercept. Objective:...
13.
Zografos L, Andrews E, Wolin D, Calingaert B, Davenport E, Hollis K, et al.
Pharmaceut Med
. 2020 Jan;
33(3):219-233.
PMID: 31933286
Background: As part of the risk-management plan for aflibercept in the European Union, materials have been developed to educate physicians and patients in Europe on the safe use of aflibercept....
14.
Saltus C, Vassilev Z, Zong J, Calingaert B, Andrews E, Soriano-Gabarro M, et al.
Prostate Cancer
. 2019 Jul;
2019:3425982.
PMID: 31355002
[This corrects the article DOI: 10.1155/2019/4387415.].
15.
Nance R, Vannappagari V, Smith K, Johannes C, Calingaert B, Saltus C, et al.
J Acquir Immune Defic Syndr
. 2019 May;
81(5):572-577.
PMID: 31107299
Background: Guidelines for initial antiretroviral treatment (ART) regimens have evolved, with integrase strand transfer inhibitors (INSTIs) increasingly prominent. Research on virologic failure (VF) with INSTI therapy is predominantly from clinical...
16.
Saltus C, Vassilev Z, Zong J, Calingaert B, Andrews E, Soriano-Gabarro M, et al.
Prostate Cancer
. 2019 Mar;
2019:4387415.
PMID: 30886751
Background: New therapies for castration-resistant prostate cancer (CRPC) may be associated with increased risk of second primary malignancies (SPM). We therefore estimated the population-based incidence of SPM among patients with...
17.
Margulis A, Fortuny J, Kaye J, Calingaert B, Reynolds M, Plana E, et al.
Epidemiology
. 2018 Nov;
30(2):e8-e9.
PMID: 30489349
No abstract available.
18.
Castellsague J, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Calingaert B, et al.
Pharmacoepidemiol Drug Saf
. 2018 Jul;
27(9):953-961.
PMID: 30043552
Purpose: The purpose of the study is to evaluate the effectiveness of risk minimization measures-labeling changes and communication to health care professionals-recommended by the European Medicines Agency for use of...
19.
Saltus C, Calingaert B, Candrilli S, Lorenzo M, Dyachkova Y, Otto T, et al.
Sarcoma
. 2018 Jun;
2018:5671926.
PMID: 29849478
We conducted a retrospective cohort study using data compiled from the regional German cancer registries by the Centre for Cancer Registry Data (ZfKD) at the Robert Koch Institut (RKI) to...
20.
Margulis A, Fortuny J, Kaye J, Calingaert B, Reynolds M, Plana E, et al.
Epidemiology
. 2018 May;
29(5):e41-e42.
PMID: 29794511
No abstract available.